乳腺癌雌孕激素受体与DNA倍体表达的临床意义

Clinical significance of ER、PR and DNA ploid Expression in breast cancer

目的 :探讨乳腺癌雌、孕激素受体和DNA倍体表达的临床意义。方法 :采用高敏感的SP免疫组化法检测雌、孕激素受体和采用流式细胞检测DNA倍体在乳腺癌中的表达。结果 :143例乳腺癌中ER(+) /PR(+)者 78例 ,ER(+) /PR(- ) 18例 ,ER(- ) /PR(+) 12例 ,ER(- ) /PR(- ) 35例 ,ER(+)者 96例 ,占 6 7 1% ,PR(+)者 90例 ,占 6 2 9%。ER表达状况与年龄、肿瘤大小、淋巴结转移无关 (P >0 0 5) ,ER(+)者预后较好 ,3年生存率为 93 75% ,ER(- )者仅 53 2 % ,两者显著差别P <0 0 5,56例乳腺癌中 ,二倍体 2 2例 ,四倍体 9例 ,异倍体 2 5例 ,DNA倍体与年龄、肿瘤大小、淋巴结转移无关 ,(P >0 0 5) ,而二、四倍体肿瘤预后较好 ,3年生存率分别为 95 5%和 88 7% ,5年生存率分别为 90 2 %和77 8% ,异倍体预后较差 ,3年生存率仅 6 0 % ,5年生存率仅 56 %。结论 :ER和DNA倍体表达和预后密切相关 (P >0 0 5) ,可作为判断预后的指标。

Objective:To evaluate the clinical significance of ER、PR and DNA ploid expression in the breast cancer Methods:ER、PR in patients with breast cancer were examined by the method of ABC immunohistochemistry and DNA ploid were analyzed by FCM Results:In 143 patients with breast cancer,ER(+)PR(+)were in 78 cases ER(+)PR(-)in18,ER(-)PR(+)in 12 and ER(-)PR(-)in 35 All of ER(+)were 96 cases(67 1%) and PR(+)in 90(62 9%),ER(-)in47(32 8%)PR(-)in 53(37%) There were no relation ship between ER(+)or (-)expression and age,tumor size,lymphnode metastasis ER(+)cases have a good prognosis,3 years survivel rate was 93 7% and ER(-)case was 53 2%( P >0 05) In 56 patients,diploid in 22 cases,tetraploid in 9 and aneuploid in 25 There were no relationship between DNA ploid and age、tumor size,lymphnod metastasis Tumour of diploid and tetraploid has a good prognosis, 3 years survival rate was 95 5% and 88 7% respectively, 5 years survival rate was 90 2% and 77 8% respectively Aneu ploid has a bad prognosis,3 years survival rate was 60% and 5 years survival rate was 56% Conclusions:There were significant relationship between ER,DNA ploid expression and prognosis( P <0 05);they may be a important predictors to decide the prognosis of breast cancer